Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/07/12 | Notice of Effectiveness |
|
1 | ||
| 05/07/12 | Prospectus filed pursuant to Rule 424(b)(3) |
|
88 | ||
| 04/25/12 | General form of registration statement for all companies including face-amount certificate companies |
|
 |
99 | |
| 04/02/12 | Annual report pursuant to Section 13 and 15(d) |
|
|
76 | |
| 04/02/12 | Prospectus filed pursuant to Rule 424(b)(5) |
|
67 | ||
| 04/02/12 | Current report filing |
|
82 | ||
| 04/02/12 | Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT |
|
2 | ||
| 04/02/12 | Statement of changes in beneficial ownership of securities |
|
2 | ||
| 04/02/12 | Statement of changes in beneficial ownership of securities |
|
2 | ||
| 04/02/12 | Statement of changes in beneficial ownership of securities |
|
2 |